• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, August 26, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Kansas State University virologists publish new findings on SARS-CoV-2 treatment option

Bioengineer by Bioengineer
July 2, 2021
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Kansas State University

MANHATTAN, KANSAS — A recent study by Kansas State University virologists demonstrates successful postinfection treatment for SARS-CoV-2, the virus that causes COVID-19.

College of Veterinary Medicine researchers Yunjeong Kim and Kyeong-Ok “KC” Chang published the study in the prestigious journal Proceedings of the National Academy of Sciences of the United States of America, or PNAS. They found that animal models infected with SARS-CoV-2 and treated with a deuterated protease inhibitor had significantly increased survival and decreased lung viral load.

The results suggest that postinfection treatment with inhibitors of proteases that are essential for viral replication may be an effective treatment against SARS-CoV-2. These protease inhibitors are a class of antiviral drugs that prevent viral replication by selectively binding to viral proteases and blocking the activation of proteins that are necessary for the production of infectious viral particles.

“We developed the protease inhibitor GC376 for treating a fatal coronavirus infection in cats, which is now under commercial development as an investigational new animal drug,” said Kim, associate professor of diagnostic medicine and pathobiology. “After COVID-19 emerged, many research groups reported that this inhibitor is also effective against the coronavirus that causes COVID-19, and many are currently pursuing the development of protease inhibitors as a treatment.”

Kim and Chang modified GC376 using a tool called deuteration to test its efficacy against SARS-CoV-2.

“Treating SARS-CoV-2-infected mice with deuterated GC376 significantly improved survival, viral replication in lungs and weight losses, which shows the efficacy of the antiviral compound,” said Chang, professor of diagnostic medicine and pathobiology. “The results suggest deuterated GC376 has a potential for further development, and this deuteration method can be utilized to other antiviral compounds to generate potent inhibitors.”

The virologists are continuing to develop improved inhibitors using various methods. Deuterated GC376 is currently being evaluated for further potential development.

###

Previous work done by Kim and Chang is continuing development through licensing agreements with industry partners.

Media Contact
Kyeong-Ok Chang
[email protected]

Original Source

https://www.k-state.edu/media/newsreleases/2021-07/chang-kim-pnas-covid.html

Related Journal Article

http://dx.doi.org/10.1073/pnas.2101555118

Tags: BiologyInfectious/Emerging DiseasesMedicine/HealthVirology
Share13Tweet8Share2ShareShareShare2

Related Posts

Stress, Self-Control, and Mobile Addiction in Nursing

August 26, 2025

Enhancing Diabetes Detection via HbA1c in Emergency Care

August 26, 2025

Link Between Immune Inflammation and Diabetic Retinopathy Stages

August 26, 2025

Spatial Cues Drive Multiplexed Theta Coding

August 26, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    147 shares
    Share 59 Tweet 37
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Stress, Self-Control, and Mobile Addiction in Nursing

Enhancing Diabetes Detection via HbA1c in Emergency Care

Urban Planning Unequally Burdens Traveller Sites Environmentally

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.